Ganse EV, Danchin N, Mah I, et al
When your medication must remain sterile throughout its shelf life and yours is an injectable product, the difference between a USP 797-compliant facility and a non-compliant one is not trivial
One such effective option that has been attracting a lot of attention lately is semaglutide
This test is inexpensive and adds meaningful context for metabolic monitoring
Meanwhile, semaglutide 2.4 mg daily (Wegovy, Novo Nordisk) resulted in weight loss of up to 13.9% (95% CI, 11%-16.7%) after 68 weeks of therapy, whereas liraglutide at 3 mg daily (Saxenda, Novo Nordisk) reduced weight by up to 5.8% (95% CI, 3.6%-8%) after 26 weeks
Behavioural testing was carried out to ascertain the effect of liraglutide on disease progression